Discretion and local health policy implementation: street-level bureaucrats and integrative and complementary therapies in Santos' local health units. [PDF]
Prim Health Care Res Dev, 2022 Macena A, Oliveira VE.
europepmc +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Early ambulation and dhikr complementary therapies effect on intestinal peristaltic in post-open cholecystectomy patients. [PDF]
Rev Bras Enferm, 2023 Wilandika A, Gartika N, Nurfarida E.
europepmc +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Complementary and alternative therapies for osteoarthritis
Indian Journal of Rheumatology, 2006 R Handa, A Goel
doaj +1 more source
Complementary therapies intervention in Parkinson's disease: systematic review and meta-analysis. [PDF]
Front NeurolSabbadin F +5 more
europepmc +1 more source
Effectiveness of Complementary Therapies in Cancer Patients: A Systematic Review. [PDF]
Int J Environ Res Public Health, 2021 Guerra-Martín MD +2 more
europepmc +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Complementary Therapies of Diabetic Peripheral Neuropathy and Intermittent Claudication. [PDF]
Healthcare (Basel)Ng SY.
europepmc +1 more source